Logo image of 56S1.DE

SARTORIUS STEDIM BIOTECH (56S1.DE) Stock Fundamental Analysis

FRA:56S1 - Deutsche Boerse Ag - FR0013154002 - Common Stock - Currency: EUR

197.5  +0.1 (+0.05%)

Fundamental Rating

5

Overall 56S1 gets a fundamental rating of 5 out of 10. We evaluated 56S1 against 17 industry peers in the Life Sciences Tools & Services industry. Both the profitability and the financial health of 56S1 get a neutral evaluation. Nothing too spectacular is happening here. While showing a medium growth rate, 56S1 is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

56S1 had positive earnings in the past year.
56S1 had a positive operating cash flow in the past year.
Each year in the past 5 years 56S1 has been profitable.
Each year in the past 5 years 56S1 had a positive operating cash flow.
56S1.DE Yearly Net Income VS EBIT VS OCF VS FCF56S1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

1.2 Ratios

56S1 has a Return On Assets (2.46%) which is in line with its industry peers.
With a Return On Equity value of 5.14%, 56S1 perfoms like the industry average, outperforming 52.94% of the companies in the same industry.
56S1's Return On Invested Capital of 4.36% is in line compared to the rest of the industry. 56S1 outperforms 41.18% of its industry peers.
The Average Return On Invested Capital over the past 3 years for 56S1 is above the industry average of 6.91%.
The last Return On Invested Capital (4.36%) for 56S1 is well below the 3 year average (10.41%), which needs to be investigated, but indicates that 56S1 had better years and this may not be a problem.
Industry RankSector Rank
ROA 2.46%
ROE 5.14%
ROIC 4.36%
ROA(3y)7.81%
ROA(5y)9.13%
ROE(3y)17.3%
ROE(5y)20.06%
ROIC(3y)10.41%
ROIC(5y)14.57%
56S1.DE Yearly ROA, ROE, ROIC56S1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30

1.3 Margins

56S1 has a Profit Margin of 7.15%. This is in the better half of the industry: 56S1 outperforms 70.59% of its industry peers.
56S1's Profit Margin has declined in the last couple of years.
The Operating Margin of 56S1 (14.05%) is comparable to the rest of the industry.
In the last couple of years the Operating Margin of 56S1 has declined.
56S1 has a better Gross Margin (43.89%) than 70.59% of its industry peers.
56S1's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 14.05%
PM (TTM) 7.15%
GM 43.89%
OM growth 3Y-22.38%
OM growth 5Y-9.98%
PM growth 3Y-24.01%
PM growth 5Y-17.3%
GM growth 3Y-6.9%
GM growth 5Y-3.53%
56S1.DE Yearly Profit, Operating, Gross Margins56S1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40 50

5

2. Health

2.1 Basic Checks

56S1 has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for 56S1 has been increased compared to 1 year ago.
Compared to 5 years ago, 56S1 has more shares outstanding
Compared to 1 year ago, 56S1 has an improved debt to assets ratio.
56S1.DE Yearly Shares Outstanding56S1.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
56S1.DE Yearly Total Debt VS Total Assets56S1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

2.2 Solvency

An Altman-Z score of 3.95 indicates that 56S1 is not in any danger for bankruptcy at the moment.
56S1 has a better Altman-Z score (3.95) than 76.47% of its industry peers.
56S1 has a debt to FCF ratio of 5.03. This is a neutral value as 56S1 would need 5.03 years to pay back of all of its debts.
56S1 has a Debt to FCF ratio (5.03) which is in line with its industry peers.
56S1 has a Debt/Equity ratio of 0.72. This is a neutral value indicating 56S1 is somewhat dependend on debt financing.
56S1 has a worse Debt to Equity ratio (0.72) than 70.59% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.72
Debt/FCF 5.03
Altman-Z 3.95
ROIC/WACC0.52
WACC8.38%
56S1.DE Yearly LT Debt VS Equity VS FCF56S1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.3 Liquidity

56S1 has a Current Ratio of 1.85. This is a normal value and indicates that 56S1 is financially healthy and should not expect problems in meeting its short term obligations.
56S1 has a Current ratio of 1.85. This is in the better half of the industry: 56S1 outperforms 76.47% of its industry peers.
A Quick Ratio of 1.14 indicates that 56S1 should not have too much problems paying its short term obligations.
56S1 has a Quick ratio of 1.14. This is in the better half of the industry: 56S1 outperforms 64.71% of its industry peers.
Industry RankSector Rank
Current Ratio 1.85
Quick Ratio 1.14
56S1.DE Yearly Current Assets VS Current Liabilites56S1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

6

3. Growth

3.1 Past

56S1 shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 4.97%.
56S1 shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 4.19% yearly.
Looking at the last year, 56S1 shows a small growth in Revenue. The Revenue has grown by 5.21% in the last year.
Measured over the past years, 56S1 shows a quite strong growth in Revenue. The Revenue has been growing by 14.05% on average per year.
EPS 1Y (TTM)4.97%
EPS 3Y-22.3%
EPS 5Y4.19%
EPS Q2Q%34.88%
Revenue 1Y (TTM)5.21%
Revenue growth 3Y-1.25%
Revenue growth 5Y14.05%
Sales Q2Q%11.65%

3.2 Future

The Earnings Per Share is expected to grow by 21.89% on average over the next years. This is a very strong growth
56S1 is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.79% yearly.
EPS Next Y23.98%
EPS Next 2Y25.51%
EPS Next 3Y24.81%
EPS Next 5Y21.89%
Revenue Next Year8.49%
Revenue Next 2Y9.67%
Revenue Next 3Y10.37%
Revenue Next 5Y10.79%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
56S1.DE Yearly Revenue VS Estimates56S1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2B 4B 6B
56S1.DE Yearly EPS VS Estimates56S1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2 4 6 8 10

1

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 51.97, the valuation of 56S1 can be described as expensive.
56S1's Price/Earnings ratio is a bit more expensive when compared to the industry. 56S1 is more expensive than 76.47% of the companies in the same industry.
When comparing the Price/Earnings ratio of 56S1 to the average of the S&P500 Index (26.34), we can say 56S1 is valued expensively.
A Price/Forward Earnings ratio of 35.82 indicates a quite expensive valuation of 56S1.
Compared to the rest of the industry, the Price/Forward Earnings ratio of 56S1 indicates a slightly more expensive valuation: 56S1 is more expensive than 76.47% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.19, 56S1 is valued quite expensively.
Industry RankSector Rank
PE 51.97
Fwd PE 35.82
56S1.DE Price Earnings VS Forward Price Earnings56S1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

56S1's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. 56S1 is more expensive than 76.47% of the companies in the same industry.
56S1's Price/Free Cash Flow ratio is in line with the industry average.
Industry RankSector Rank
P/FCF 32.94
EV/EBITDA 30.15
56S1.DE Per share data56S1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30 40

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
56S1's earnings are expected to grow with 24.81% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.17
PEG (5Y)12.39
EPS Next 2Y25.51%
EPS Next 3Y24.81%

3

5. Dividend

5.1 Amount

56S1 has a yearly dividend return of 0.34%, which is pretty low.
Compared to an average industry Dividend Yield of 0.73, 56S1 is paying slightly less dividend.
With a Dividend Yield of 0.34, 56S1 pays less dividend than the S&P500 average, which is at 2.40.
Industry RankSector Rank
Dividend Yield 0.34%

5.2 History

The dividend of 56S1 has a limited annual growth rate of 4.44%.
Dividend Growth(5Y)4.44%
Div Incr Years0
Div Non Decr Years1
56S1.DE Yearly Dividends per share56S1.DE Yearly Dividends per shareYearly Dividends per share 2022 2023 2024 2025 0.5 1

5.3 Sustainability

32.84% of the earnings are spent on dividend by 56S1. This is a low number and sustainable payout ratio.
The dividend of 56S1 is growing, but earnings are growing more, so the dividend growth is sustainable.
DP32.84%
EPS Next 2Y25.51%
EPS Next 3Y24.81%
56S1.DE Yearly Income VS Free CF VS Dividend56S1.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M
56S1.DE Dividend Payout.56S1.DE Dividend Payout, showing the Payout Ratio.56S1.DE Dividend Payout.PayoutRetained Earnings

SARTORIUS STEDIM BIOTECH

FRA:56S1 (6/18/2025, 7:00:00 PM)

197.5

+0.1 (+0.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)04-16 2025-04-16/bmo
Earnings (Next)07-22 2025-07-22
Inst Owners10.65%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap19.22B
Analysts77.78
Price Target248.41 (25.78%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.34%
Yearly Dividend0.71
Dividend Growth(5Y)4.44%
DP32.84%
Div Incr Years0
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.91%
Min EPS beat(2)7.63%
Max EPS beat(2)22.18%
EPS beat(4)2
Avg EPS beat(4)0.98%
Min EPS beat(4)-20.27%
Max EPS beat(4)22.18%
EPS beat(8)2
Avg EPS beat(8)-16.9%
EPS beat(12)2
Avg EPS beat(12)-16.88%
EPS beat(16)5
Avg EPS beat(16)-11.85%
Revenue beat(2)2
Avg Revenue beat(2)3.21%
Min Revenue beat(2)2.91%
Max Revenue beat(2)3.52%
Revenue beat(4)3
Avg Revenue beat(4)0.7%
Min Revenue beat(4)-5.11%
Max Revenue beat(4)3.52%
Revenue beat(8)4
Avg Revenue beat(8)-1.35%
Revenue beat(12)4
Avg Revenue beat(12)-1.7%
Revenue beat(16)8
Avg Revenue beat(16)12.23%
PT rev (1m)0%
PT rev (3m)-3.31%
EPS NQ rev (1m)1.98%
EPS NQ rev (3m)0.57%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.03%
Revenue NQ rev (1m)-0.03%
Revenue NQ rev (3m)-3.74%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.05%
Valuation
Industry RankSector Rank
PE 51.97
Fwd PE 35.82
P/S 6.73
P/FCF 32.94
P/OCF 21.86
P/B 4.84
P/tB N/A
EV/EBITDA 30.15
EPS(TTM)3.8
EY1.92%
EPS(NY)5.51
Fwd EY2.79%
FCF(TTM)6
FCFY3.04%
OCF(TTM)9.04
OCFY4.58%
SpS29.36
BVpS40.81
TBVpS-5.43
PEG (NY)2.17
PEG (5Y)12.39
Profitability
Industry RankSector Rank
ROA 2.46%
ROE 5.14%
ROCE 5.47%
ROIC 4.36%
ROICexc 4.84%
ROICexgc 15.14%
OM 14.05%
PM (TTM) 7.15%
GM 43.89%
FCFM 20.42%
ROA(3y)7.81%
ROA(5y)9.13%
ROE(3y)17.3%
ROE(5y)20.06%
ROIC(3y)10.41%
ROIC(5y)14.57%
ROICexc(3y)10.84%
ROICexc(5y)15.37%
ROICexgc(3y)26.31%
ROICexgc(5y)36.49%
ROCE(3y)13.07%
ROCE(5y)18.3%
ROICexcg growth 3Y-36.77%
ROICexcg growth 5Y-16.49%
ROICexc growth 3Y-43.34%
ROICexc growth 5Y-25.09%
OM growth 3Y-22.38%
OM growth 5Y-9.98%
PM growth 3Y-24.01%
PM growth 5Y-17.3%
GM growth 3Y-6.9%
GM growth 5Y-3.53%
F-Score7
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0.72
Debt/FCF 5.03
Debt/EBITDA 4
Cap/Depr 95.85%
Cap/Sales 10.35%
Interest Coverage 2.25
Cash Conversion 123.84%
Profit Quality 285.66%
Current Ratio 1.85
Quick Ratio 1.14
Altman-Z 3.95
F-Score7
WACC8.38%
ROIC/WACC0.52
Cap/Depr(3y)182.98%
Cap/Depr(5y)186.68%
Cap/Sales(3y)13.87%
Cap/Sales(5y)12.23%
Profit Quality(3y)126.76%
Profit Quality(5y)109.63%
High Growth Momentum
Growth
EPS 1Y (TTM)4.97%
EPS 3Y-22.3%
EPS 5Y4.19%
EPS Q2Q%34.88%
EPS Next Y23.98%
EPS Next 2Y25.51%
EPS Next 3Y24.81%
EPS Next 5Y21.89%
Revenue 1Y (TTM)5.21%
Revenue growth 3Y-1.25%
Revenue growth 5Y14.05%
Sales Q2Q%11.65%
Revenue Next Year8.49%
Revenue Next 2Y9.67%
Revenue Next 3Y10.37%
Revenue Next 5Y10.79%
EBIT growth 1Y-0.84%
EBIT growth 3Y-23.35%
EBIT growth 5Y2.67%
EBIT Next Year91.76%
EBIT Next 3Y37.04%
EBIT Next 5Y27.81%
FCF growth 1Y325.99%
FCF growth 3Y7.94%
FCF growth 5Y22.24%
OCF growth 1Y45.08%
OCF growth 3Y5.11%
OCF growth 5Y21.32%